- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05414357
Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer (ICANSLEEP)
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Carine SEGURA-DJEZZAR, MD
- Phone Number: +33 2 31 45 50 02
- Email: c.segura.djezzar@baclesse.unicancer.fr
Study Locations
-
-
-
Caen, France, 14000
- Recruiting
- Centre François Baclesse
-
Contact:
- Carine SEGURA-DJEZZAR, MD
- Phone Number: +33 2 31 45 50 02
- Email: c.segura.djezzar@baclesse.unicancer.fr
-
Principal Investigator:
- Carine SEGURA-DJEZZAR, MD
-
Sub-Investigator:
- Christelle LEVY, MD
-
Sub-Investigator:
- George EMILE, MD
-
Sub-Investigator:
- Adeline MOREL, MD
-
Caen, France, 14000
- Not yet recruiting
- Inserm-Ephe-Unicaen U1077
-
Contact:
- Fausto VIADER, PhD
-
Principal Investigator:
- Fausto VIADER, PhD
-
Sub-Investigator:
- Vincent DE LA SAYETTE, PhD
-
Sub-Investigator:
- Olivier MARTINAUD, PhD
-
Sub-Investigator:
- Pierre DENISE, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 45 to 65 years
- Patient with operated localized breast cancer who may or may not be starting adjuvant chemotherapy
- Patient with education level 3 "end of primary education"
- Patient with a good command of the French language
- Patient with access to the Internet from a computer at home
- Patient having signed the consent to participate in the study
- Patient with no pre-existing cognitive impairment at the time of cancer diagnosis
- Patient with a sleep complaint (ISI > 7)
Exclusion Criteria:
- Patient with metastatic cancer
- Patient with a primary cancer other than breast cancer
- Patient with a history of neurological damage
- Patient with treated sleep apnea
- Patient with drug use or alcohol abuse (≥3 drinks/day on average and/or >10 drinks/week)
- Patient with a treatment that has not been stabilized for at least 3 months (hypnotics, antidepressants, anxiolytics)
- Patient with a personality disorder and/or an evolving psychiatric pathology
- Patient with a contraindication to MRI (claustrophobia, metallic objects in the body)
- Patient with an uncorrected vision problem
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with chemotherapy
|
Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:
Other Names:
|
Active Comparator: Patients without chemotherapy
|
Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:
Other Names:
|
Active Comparator: cancer-free volunteers
|
Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ratio of total sleep time to time spent in bed and the number of awakenings lasting more than one minute measured by polysomnography with actimeter
Time Frame: At 6 months
|
At 6 months
|
Amplitude of activity-rest rhythm measured with actimeter
Time Frame: At 6 months
|
At 6 months
|
Acrophase of activity-rest rhythm measured with actimeter
Time Frame: At 6 months
|
At 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-A00437-36
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Functional Magnetic Resonance Imaging at rest and in activation with attentional task
-
RWTH Aachen UniversityUnknownTransposition of the Great Arteries | Artery Switch OperationGermany
-
University of BernClinic SuedhangNot yet recruitingAlcohol Use DisorderSwitzerland
-
Supernus Pharmaceuticals, Inc.TerminatedAttention Deficit Hyperactivity Disorder (ADHD) | Impulsive AggressionUnited States
-
Instituto do Cancer do Estado de São PauloTerminatedGastrointestinal Neoplasms | Gastrointestinal Hemorrhage
-
National Cancer Institute (NCI)Not yet recruiting
-
National Cancer Institute (NCI)RecruitingStage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal CarcinomaUnited States, China
-
Washington University School of MedicineActive, not recruitingSleep | Sedation ComplicationUnited States
-
Organon and CoBayerCompleted
-
University of the AegeanCompletedOsteopenia or OsteoporosisGreece